Physician profile
Thomas D Holt
NPI 1306848494
$603.72
in general payments reported to CMS, 2019-2025
16 companies · $21.84 in 2025
The $21.84 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $83.01 · 2021: $52.79 · 2022: $90.78 · 2023: $18.63 · 2024: $19.14 · 2025: $21.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $59.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $59.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $118.71 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $78.23 | 2021-2025 | Nuplazid |
| Sanofi-Aventis U.S. LLC | $57.54 | 2019 | |
| Avanir Pharmaceuticals, INC. | $51.04 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $42.91 | 2020-2022 | |
| Pfizer INC. | $32.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $30.60 | 2019-2020 | |
| Lilly USA, LLC | $29.45 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.15 | 2019 | |
| Merck Sharp & Dohme LLC | $28.42 | 2020 | |
| Amarin Pharma, INC. | $25.00 | 2019 | |
| Ucb, INC. | $19.14 | 2024 | Nayzilam |
| Neurocrine Biosciences, INC. | $18.63 | 2023 | Ingrezza |
| Novo Nordisk INC | $17.04 | 2019 | |
| Astellas Pharma US INC | $14.37 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.